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Abstract 
Background: Human cytomegalovirus (HCMV) is a common virus that infects people of all ages. HCMV 
infection is an important and common complication in immunocompromised patients, especially transplant 
recipients. Antigenemia test and real-time PCR are one of the most common assays for diagnosis and monitoring of 
CMV infections. The aims of this study were to compare two common detection methods in order to identify 
clinically useful CMV infection in kidney transplant patients. Materials and Methods: One hundred and fifty 
peripheral blood samples from kidney transplant patients, including 78 men and 72 women aged from 4 to 73 
years; with mean age of 36 years, collected during March 2016 to June 2016. Then samples were investigated for 
pp65-antigen on polymorphonuclear cells and HCMV DNA viral load on plasma and whole blood. Results: Out of 
150 samples analyzed, HCMV DNA was detected in 47(31.33%) cases; with 26 (55.32%) and 21(44.68%) cases in 
men and women, respectively. The pp65 antigen was detected in 42(28%) casas; with 23 (54.76%) and 19 
(45.24%) cases in men and women, respectively. Of the 150 samples, 42 (28%) were positive for both assays and 
108 (72%)were negative. Conclusion: Our findings showed both tests were significantly correlated and can be 
useful for monitoring of CMV infection. Hence, higher viral loads have been found to be associated with increase 
of disease complication, Real- time PCR is more suitable. The findings merit more investigations involving larger 
numbers of samples.  
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Human Cytomegalovirus (HCMV) is a 
member of the Herpesviridae family and is a 
ubiquitous virus with worldwide distribution (1, 2). 
Its seroprevalence in human is more than 70% and 
about 90% in developing countries (3, 4). HCMV is 
spread from an infected person by direct contact. 
People with CMV may shed the virus in body fluids, 
such as urine, saliva, blood, tears, semen, and breast 
milk. As well as, also organ transplants are one of the 
possible modes of transmission (5, 6). HCMV is one 
of the most common opportunistic virus that is 
controlled in individuals with normal immune system 
but established in immunocompromised patients or 
reactivated in transplant recipients (4, 7, 8). This 
infection occurs due to transmission from the 
transplanted organ, due to reactivation of latent 
infection, or after a primary infection in seronegative 
patients and can be defined as follows: latent 
infection, active infection, viral syndrome or invasive 
disease (9). ''Active CMV infection occurs in 30-75 % 
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of transplant recipients, with a mortality rate of 5%'' 
(4). Cytomegalovirus infection is one of the main 
infectious morbidities after renal transplant, leading to 
direct effects, such as disease, characterized by the 
viral syndrome or by the invasive disease, and to 
indirect effects, such as increased risk of acute 
rejection and chronic graft dysfunction (10). 
  The prevention of CMV disease is therefore a 
major goal in the clinical management of these 
patients. Cytomegalovirus disease can be prevented 
by prophylaxis or by preemptive therapy (9). 
Preemptive therapy reduces the incidence and the 
severity of the CMV disease; however, it depends on 
early laboratory identification of those at a high risk 
of disease (11). There are several diagnostic tests for 
detection of CMV, including serological tests, cell 
culture, antigenemia, polymerase chain reaction 
(PCR), immunohistochemistry, nucleic acid 
sequence-based amplification (NASBA) and hybrid 
capture assay (12-14). The key to efficient and 
effective management of CMV infection in these 
patients is to develop a highly sensitive and 
quantitative detection method capable of quantifying 
the CMV viral load and rapidly identifying patients at 
high risk of developing CMV disease, and monitoring 
the preemptive antiviral therapeutic strategies (15). 
Antigenemia and PCR tests use to for detection of 
active CMV infection by the identification of pp65 
antigen-positive and CMV DNA in blood (16, 17). 
Antigenemia assay is widely used to monitor 
transplant recipients patients. This method aims to 
detect pp65 antigen expressed in CMV infected all 
nucleated cells (ANC) using a monoclonal antibody 
(18). This method has several limitations regarding its 
use in the clinical practice: it is a manual test, blood 
samples should be processed within 6–8 hours of 
collection, and high level of technical expertise is 
required to read the slides. leukopenia is one of the 
clinical symptoms of CMV infection. Hence, the 
evaluation the CMV pp65 antigen done in peripheral 
blood leukocytes, the interpretation of its results may 
be difficult in children and people with leucopenia. In 
this setting, qPCR is an alternative method for early 
detection of viral replication as it is not affected by 
leucopenia (19). Employing the sensitive, quick and 
specific diagnostic methods for early detection of 
CMV plays an important role in CMV prevention in 
transplant patients because the severity of CMV 
disease can reduce with using of antiviral drugs. The 
use of ganciclovir and some other antiviral drugs such 
as foscarnet and valganciclovir have reduced both the 
morbidity and mortality of HCMV disease (20). In 
this cross sectional study, a rapid commercial 
Cytomegalovirus pp65 antigenemia assay was 
compared to real-time PCR for detection and 
quantitation of CMV in clinical samples for kidney 
transplant patients. 
Methods 
All reported methods were carried out in 
accordance with the latest revision of the Declaration 
of Helsinki 1964 
Patients. From March 2016 to June 2016, one 
hundred and fifty peripheral blood samples (including 
72 females and 78 males) were collected from kidney 
recipients, admitted to Transplantation laboratory 
centers in Tehran city for CMV pp65 antigen and 
CMV DNA evaluation. A total of 150 blood samples 
were collected in citrate-anticoagulated vials. 
HCMV pp65 antigenemia assay. This 
technique was performed within 4 hours of specimen 
collection. samples were processed for antigenemia 
within 4-5 hours, and the others were stored for 
quantitative plasma DNA determination. The 
determination of HCMV antigenemia was performed 
using a (CMV Groningen, Netherlands IQ Products, 
Brite TM Turbu) according to the manufacturer's 
instructions. The number of pp65-positive 
polymorphonuclear leukocytes (PMNL) was 
determined after staining with specific fluorescein 
isothiocyanate-labelled monoclonal antibodies and 
results were expressed as the number of fluorescing 
cells per 30,000 PMNL. 
DNA extraction. Total nucleic acids were 
extracted from 200 μl of EDTA-anticoagulant whole 
blood with using of QIAamp DNA minikit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
instructions. Then the extracted DNA was stored at -
20°C. 
HCMV DNA quantitation. HCMV DNA 
quantitation was carried out by a commercially 
available Nanogen Q-CMV Real Time Complete Kit 
(Nanogen Advanced Diagnostics, Torino, Italy) that 
has the UL123 gene as target region. This method was 
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performed according to the manufacturer's 
recommendations.  PCR test were carried out as 
follows: pre-denaturation at 95°C for 15 min, 95°C 
for 5 s, 60°C for 20 s and 72°C for 15 s for 45 cycles. 
PCR reactions were performed using a Rotor Gene 
6000 Instrument (Corbett Research, Doncaster, 
Australia).  
Results 
Out of 150 samples analyzed, HCMV DNA 
was detected in 47(31.33%) cases; with 26 (55.32%) 
and 21(44.68%) cases in male and female, 
respectively. Viral load in HCMV positive samples 
ranged from 71 copies/ml to 900×103copies/ml 
(Table 1). All specimens were positive for beta-globin 
DNA, confirming the quality of the DNA 
preparations. pp65 antigen was detected in 42(28%) 
casas; with 23 (54.76%) and 19 (45.24%) cases in 
male and female, respectively. Leukocytes count 
range in CMV pp65 antigen-positive were from 
5×103/µl to 12×103/µl (Table 2). Of the 150 samples, 
42 (28%) were positive for both assays and the rest 
were negative. five pp65-negative samples  had 
HCMV DNA levels lower than 100 copies/ml. There 
was no sample that be pp65 antigen positive, but a 
Real time PCR negative. Comparison of results 
showed that no significant differences between the 
number of positive and negative samples obtained by 
two methods (P-value=0.61). Sensitivity and 
specificity of pp65 antigenemia assay and Real-time 
PCR method were 89.36% and 100%, respectively.  
Discussion 
Cytomegalovirus (CMV) is a genus of viruses 
in the Herpesviridae family and is ubiquitous in the 
human population (21). It is one of the main agents 
that infects up to 60−100% of people in adulthood 
(22). After primary infection, CMV is becomes 
dormant in its host and is not eradicated and may be 
reactivated under different conditions such as 
immunosuppression and inflammation (23, 24). CMV 
is a well-known pathogen in individuals with 
immunosuppressed including transplant recipients 
(25-27).  
The incidence of CMV infection varies by the 
type of organ transplant, the serostatus of donor and 
recipient, and the prevention strategies used. After 
transplantation CMV may be activated and replicated, 
which might cause prolonged hospitalization, 
increasing the post-transplant costs and the 
threatening of new kidney and the life of recipient. 
Therefore, the prevention of CMV disease is a major 
goal in the management of kidney transplant patients 
and a reliable and sensitive laboratory techniques for 
diagnosis of CMV infection before the onset of 
symptoms will be pivotal (28, 29). Reducing the 
impact of CMV infection in transplant recipients is 
required by improving at diagnosis, prevention, and 
treatment. Despite these improvements in its 
diagnosis and therapy, CMV still has a major 
outcome on transplant patients (13). PP65 
antigenemia and real-time CMV PCR are rapid 
diagnostic methods for detection of CMV infection 
and monitoring of transplant patients to reducing its 
outcomes (16, 30). 
Table1. Diagnosis of CMV infection by Real-time PCR assay 
 Number Age                                     
    
Male                    Female                           
Gender 
 




Positive cases 47     32 31 26 21 71 -900×103 
Negative cases 103     40 35 52 51 Not seen 
Total 150   78 72  
 
Table2. Diagnosis of CMV infection by pp65 antigen assay 
 Number                 Age                 
                      
   Male                 Female                           
        Gender 
 
Male            Female 
Positive cases 42     34 32 23 19 
Negative cases 108     37 36 57 51 
Total 150   80 70 
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 In this survey, we tried to show a good 
association between CMV and DNA measurements 
obtained using a commercial quantitative PCR assay 
and the pp65 antigenemia results. Our findings 
indicated that the sensitivity of pp65 antigenemia 
assay was lower than that real-time PCR test in 
screening and detection of CMV infection. This 
finding were consistent with the results of other 
studies that performed in Finland, Italy, Netherlands, 
United Kingdom, France and Iran (4, 8, 20, 31-35). 
Khansarinejad et al. suggests that the antigenemia 
method for monitoring HCMV reactivation could be 
substituted by the qPCR assay (20). Rangbar-Kermani 
et al. demonstrated that real time PCR assay is more 
sensitive for viral load determination, especially in 
some infection with low level of viral load and 
therefore, this test is an effective tool for starting 
preemptive therapy or monitoring the efficacy of anti 
CMV therapy (8).  
Real time-PCR has been considered the gold 
standard test for early diagnosis of CMV replication 
and antiviral therapy and has several advantages such 
as fast method, easy to handle, sensitive assay, 
requires a small volume of sample, can be done on 
leukopenia patients, less influenced by the quality of 
sample. Also quantification of CMV by real-time 
PCR in body fluid has been shown to be useful in 
clinical contexts for monitoring of transplant 
recipients and antiviral therapy. In which higher viral 
loads have been found to be associated with increase 
of disease complication. Therefore, quantitative PCR-
based assays might be too sensitive for clinical 
purposes (36).  
In addition, this assay is expensive and its 
sample preparation is usually the most time-
consuming (9). Therefore, the costs of this test are too 
high for implementation in public health hospitals.  
In conclusion, the measurement of viral load 
by real-time PCR appears to be an important tool in 
the prediction, diagnosis of active CMV disease in 
immuno-compromised transplant subjects, for 
differentiating latent from active infection. Hence, 
pp65 antigen has acceptable sensitivity in detection of 
CMV infection in kidney transplant that this test can 
be replacement real time PCR in low income 
countries for screening in a population of patients.  
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